Within the In-Vitro Diagnostics (IVD) Market , clinical chemistry holds the largest share at 36%, reflecting its essential role in routine health monitoring and disease diagnosis. According to the MRFR report, clinical chemistry encompasses tests that measure biochemical markers in blood and other body fluids, including glucose, cholesterol, electrolytes, and enzymes. These tests are fundamental for diagnosing and managing chronic conditions such as diabetes, kidney disease, and liver disorders. The segment’s dominance is driven by the high volume of routine testing performed in hospitals and clinical laboratories.
While clinical chemistry leads, molecular diagnostics is the fastest-growing segment. This segment leverages techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and other genetic analysis methods to detect specific genetic sequences, identify pathogens, and characterize diseases at the molecular level. Molecular diagnostics is critical for infectious disease testing (including COVID-19, HIV, and tuberculosis), oncology (for identifying genetic mutations and guiding targeted therapies), and genetic testing (for inherited disorders). The market for molecular diagnostics is projected to grow from USD 20.0 billion in 2024 to USD 30.0 billion by 2035, reflecting the increasing demand for precise and personalized diagnostic tools.
Immunology is another significant segment, encompassing tests that detect antibodies, antigens, and immune responses. This segment is essential for diagnosing autoimmune diseases, allergies, and infectious diseases. The demand for immunology testing is rising due to the growing prevalence of autoimmune disorders and the need for accurate serological testing. Microbiology and hematology also contribute significantly to the market, with microbiology focused on identifying bacterial, viral, and fungal infections, and hematology covering blood cell counts and coagulation testing.
The growth of molecular diagnostics is fueled by several factors. First, the increasing incidence of cancer and infectious diseases is driving demand for precise diagnostic tools. Second, advancements in sequencing technologies are reducing costs and improving accessibility. Third, the shift towards personalized medicine is creating a need for companion diagnostics that guide treatment decisions. As these trends continue, molecular diagnostics is expected to capture an increasing share of the IVD market, complementing the established role of clinical chemistry.
